Recent developments have led us to hold a more positive outlook for Egypt's pharmaceutical and healthcare market s . An increased healthcare budget for 2015 combined with the government's efforts at developing the local manufacturing industry and combating medicine shortages and counterfeit drugs are all positive developments. We expect Egypt's relative political stabilit y and positive economic outlook to further increa se interest from foreign pharmaceutical companies .

Headline Expenditure Projections

 * Pharmaceuticals: EGP16.55bn (USD2.41bn) in 2013 to EGP17.66bn (USD2.49bn) in 2014; +6.7% in local currency terms and 3.4% in US dollar terms. Forecast broadly in line with Q414.
 * Healthcare: EGP84.76bn (USD12.33bn) in 2013 to EGP95.80bn (USD13.49bn) in 2014; +13.0% in local currency terms and 9.4% in US dollar terms. Forecast unchanged from Q414.

Full Report Details at
 - http://www.fastmr.com/prod/974411_egypt_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=101

Risk/Reward Index: An improving economic and political outlook for Egypt means that the country remains a moderately attractive commercial opportunity for multinational pharmaceutical companies. In our Q115 Pharmaceutical Risk/Reward Index (RRI) Egypt's score of 41.9 out of 100 is lower than the Q414 score of 46.4. Its status in the Middle East and Africa region has not improved and the country has dropped to 13thposition down from last quarter when it was the 12thmost attractive market in the region.

Key Trends And Developments

 * In December 2014 the Export Council of Medical Industries began a new plan for the expansion of Egyptian exports to a number of African Asian and European markets in order to make up for the loss in export trade to Libya Iraq Syria and Yemen - due to the political situations in those countries. The Export Council's promotional visit to Romania resulted in the signing of an agreement to export Egyptian medicines and medical supplies to government hospitals in Romania. Mohi Hafez a member of the Export Council confirmed that the Export Council is planning to...

The Egypt Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.

BMI's Egypt Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Egypt pharmaceutical and healthcare industry.

Key Benefits

 * Benchmark BMI's pharmaceutical and healthcare market forecasts for Egypt to test other views - a key input for successful budgeting and strategic business planning in the Egyptian pharmaceutical and healthcare market.
 * Target business opportunities and risks in the Egyptian pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Egypt.
 * Assess the activities strategy and market position of your competitors using our company profiles (including SWOTs KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis and taken together with BMI’s political economic and business environment SWOTs it gives a complete overview of market climate.

BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators supported by explicit assumptions plus analysis of key downside risks to the main forecasts:

 * Healthcare: Total healthcare expenditure (USDbn) healthcare expenditure (% of GDP) healthcare expenditure per capita (USD) hospital beds doctors and birth & mortality rates (all per ‘000 population).
 * Pharmaceutical Market: Drug expenditure in USDbn % of GDP and per capita (USD).
 * Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
 * Generic Drug Market: Generic product sales (USDbn) generic sales (% of total sales).
 * OTC Drug Market: OTC sales (USDbn & % of total sales).
 * Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against USD government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward IndexBMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry economic and demographic data points to provide indices of highest to lowest appeal to investors with each position explained.

Market SummaryA snapshot of key market characteristics including total size of the pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape

Industry DevelopmentsA focus on government healthcare reforms epidemiological trends mergers and acquisitions product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.

Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as analysis of the overall regulatory burden.

Competitive LandscapeThe competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.

Company Profiles*

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available.  Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)